Clinical trials: Advanced Refractory Solid Tumors, open to volunteers
Solid Tumor, Locally Advanced Solid Tumor
5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors
This is a Phase I study to determine the optimal biological dose (OBD) of 5-Azacitidine in combination with PD-1/PD-L1 inhibitors in patients with tumors refractory to PD-1/PD-L1 inhibitors, for which such treatments have been…
- Conditions
- Solid Tumor, Locally Advanced Solid Tumor, Metastatic Tumor
- Trial name
- NCT07404332
- Testing
- 5 Azacytidine, Pembrolizumab, Nivolumab
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- Mohammed Milhem